<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>生物制药小编 | wechat-feeds</title><link>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</link><description>“新起点，再出发”——生物医药小编与您共同关注生物制药行业热点。</description><managingEditor> (hellodword)</managingEditor><pubDate>Thu, 04 Feb 2021 11:53:22 +0800</pubDate><image><url>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</url><title>生物制药小编 | wechat-feeds</title><link>http://MzU3Nzg4NzQyNg.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>爵士制药72亿美元收购大麻素药企GW Pharma</title><link>https://mp.weixin.qq.com/s/-SGhRGe4JNhKywujvbHYSg</link><description></description><content:encoded><![CDATA[爵士制药72亿美元收购大麻素药企GW Pharma]]></content:encoded><pubDate>Thu, 04 Feb 2021 07:39:50 +0800</pubDate></item><item><title>三叶草生物新冠疫苗极具潜力</title><link>https://mp.weixin.qq.com/s/IZEOpZWpy3zGhhUvLfoGpg</link><description></description><content:encoded><![CDATA[三叶草生物新冠疫苗极具潜力]]></content:encoded><pubDate>Wed, 03 Feb 2021 09:21:47 +0800</pubDate></item><item><title>崭露头角的HER2后浪​—ZW25临床研究进展</title><link>https://mp.weixin.qq.com/s/dGZosF-Rj17Xti-wjoT7tQ</link><description></description><content:encoded><![CDATA[崭露头角的HER2后浪​—ZW25临床研究进展]]></content:encoded><pubDate>Mon, 01 Feb 2021 19:14:16 +0800</pubDate></item><item><title>小靶点，大突破：一文掌握MET抑制剂研发现状</title><link>https://mp.weixin.qq.com/s/s1dyr2i6b07Tb63uLHRiaQ</link><description></description><content:encoded><![CDATA[小靶点，大突破：一文掌握MET抑制剂研发现状]]></content:encoded><pubDate>Mon, 01 Feb 2021 19:14:16 +0800</pubDate></item><item><title>胰岛素百年史</title><link>https://mp.weixin.qq.com/s/w0svmdleeWsXPmdYe8fSOw</link><description></description><content:encoded><![CDATA[胰岛素百年史]]></content:encoded><pubDate>Sun, 31 Jan 2021 17:38:54 +0800</pubDate></item><item><title>Science Advances：安全、有效的B7-H3×4-1BB双特异抗体及其机制研究</title><link>https://mp.weixin.qq.com/s/jpC6wRx8L9RvgieUb8QrVw</link><description></description><content:encoded><![CDATA[Science Advances：安全、有效的B7-H3×4-1BB双特异抗体及其机制研究]]></content:encoded><pubDate>Sat, 30 Jan 2021 20:07:35 +0800</pubDate></item><item><title>肿瘤免疫版ADC</title><link>https://mp.weixin.qq.com/s/jALulI9sA_XPwYiI4Sesog</link><description></description><content:encoded><![CDATA[肿瘤免疫版ADC]]></content:encoded><pubDate>Sat, 30 Jan 2021 20:07:35 +0800</pubDate></item><item><title>靶向肿瘤干细胞的药物开发靶点：CD44</title><link>https://mp.weixin.qq.com/s/eRSVzDrOwf0feQNfZH-bVg</link><description></description><content:encoded><![CDATA[靶向肿瘤干细胞的药物开发靶点：CD44]]></content:encoded><pubDate>Fri, 29 Jan 2021 23:52:16 +0800</pubDate></item><item><title>哪些精彩看点？｜2021TG-Bio第二届免疫治疗技术大会最新进展</title><link>https://mp.weixin.qq.com/s/nMU7GeX1L97JIezpqfKdDA</link><description></description><content:encoded><![CDATA[哪些精彩看点？｜2021TG-Bio第二届免疫治疗技术大会最新进展]]></content:encoded><pubDate>Fri, 29 Jan 2021 23:52:16 +0800</pubDate></item><item><title>RNA疫苗十年诞生史</title><link>https://mp.weixin.qq.com/s/uiUs8TelwtxTrz72LtRXng</link><description></description><content:encoded><![CDATA[RNA疫苗十年诞生史]]></content:encoded><pubDate>Fri, 29 Jan 2021 00:19:46 +0800</pubDate></item><item><title>2021中国免疫治疗新趋势</title><link>https://mp.weixin.qq.com/s/I7465XbWKfjV5ngC629nMA</link><description></description><content:encoded><![CDATA[2021中国免疫治疗新趋势]]></content:encoded><pubDate>Fri, 29 Jan 2021 00:19:46 +0800</pubDate></item><item><title>赛诺菲、MacroGenics等多家药企布局CD123双特异性抗体</title><link>https://mp.weixin.qq.com/s/z9pdCykQaWqWWyFf1aL3QQ</link><description></description><content:encoded><![CDATA[赛诺菲、MacroGenics等多家药企布局CD123双特异性抗体]]></content:encoded><pubDate>Wed, 27 Jan 2021 16:04:21 +0800</pubDate></item><item><title>O药“胃免”之王名副其实，或重塑胃癌一线治疗格局</title><link>https://mp.weixin.qq.com/s/X9pZ4RCwUC_8NpW_kJvHxQ</link><description></description><content:encoded><![CDATA[O药“胃免”之王名副其实，或重塑胃癌一线治疗格局]]></content:encoded><pubDate>Wed, 27 Jan 2021 16:04:21 +0800</pubDate></item><item><title>游方和尚专栏 | 大分子生物分析概论（十三）：临床前LBA方法开发的策略</title><link>https://mp.weixin.qq.com/s/hK-ggqe6VZURa_qxcFV9RQ</link><description></description><content:encoded><![CDATA[游方和尚专栏 | 大分子生物分析概论（十三）：临床前LBA方法开发的策略]]></content:encoded><pubDate>Tue, 26 Jan 2021 19:24:02 +0800</pubDate></item><item><title>未来已来：肿瘤新抗原疫苗</title><link>https://mp.weixin.qq.com/s/E5VxiOVgMVeWA3xeat68Ow</link><description></description><content:encoded><![CDATA[未来已来：肿瘤新抗原疫苗]]></content:encoded><pubDate>Tue, 26 Jan 2021 19:24:02 +0800</pubDate></item><item><title>小编发布会后记-一场重新开始的旅程，因为你们而更加不同！</title><link>https://mp.weixin.qq.com/s/GipZLKT6CC4wIgNUHqfBqg</link><description></description><content:encoded><![CDATA[小编发布会后记-一场重新开始的旅程，因为你们而更加不同！]]></content:encoded><pubDate>Tue, 26 Jan 2021 19:24:02 +0800</pubDate></item><item><title>研究新发现:  肿瘤浸润的肥大细胞与抗PD-1耐药性有关</title><link>https://mp.weixin.qq.com/s/mu80GnmldDZxp9rdAHUKVw</link><description></description><content:encoded><![CDATA[研究新发现:  肿瘤浸润的肥大细胞与抗PD-1耐药性有关]]></content:encoded><pubDate>Mon, 25 Jan 2021 19:41:05 +0800</pubDate></item><item><title>免费课程 | 保护药品研发成果，这2项专利制度你必须知道！</title><link>https://mp.weixin.qq.com/s/JwibY8B0NTx6azeJUAd_sw</link><description></description><content:encoded><![CDATA[免费课程 | 保护药品研发成果，这2项专利制度你必须知道！]]></content:encoded><pubDate>Mon, 25 Jan 2021 19:41:05 +0800</pubDate></item><item><title>《2021版生物制药小编精选文章汇编》发布后记-一场重新开始的旅程</title><link>https://mp.weixin.qq.com/s/YxaSDiC82h3MPOGTMB6c9Q</link><description></description><content:encoded><![CDATA[《2021版生物制药小编精选文章汇编》发布后记-一场重新开始的旅程]]></content:encoded><pubDate>Mon, 25 Jan 2021 19:41:05 +0800</pubDate></item></channel></rss>